ISE:RYA
ISE:RYAAirlines

Ryanair Holdings (ISE:RYA) Valuation After Q3 Profit Hit From €256m Fine And Higher Traffic Guidance

Ryanair Holdings (ISE:RYA) is back in focus after third quarter earnings combined higher revenue with a sharp profit drop tied to a €256 million Italian competition fine, along with new guidance for passenger growth in 2026 and 2027. See our latest analysis for Ryanair Holdings. After this latest update, Ryanair’s share price of €28.29 sits slightly below where it started the year. Short term pressure from the Q3 profit hit contrasts with a stronger multi year total shareholder return profile...
ISE:RYA
ISE:RYAAirlines

Ryanair Profit Hit By Italian Fine Puts Regulatory Risks In Focus

Ryanair Holdings (ISE:RYA) reported an over 80% plunge in third quarter profit after a substantial fine from Italy's competition authority. The Italian regulator accused the airline of abusing a dominant market position, a claim Ryanair is appealing. The one off charge from the fine had a material impact on quarterly results, separate from usual trading performance. For investors watching ISE:RYA, this regulatory hit comes after a strong multi year share price run, with the stock up 96.1%...
ISE:RYA
ISE:RYAAirlines

Ryanair Holdings (ISE:RYA) Net Margin Surge Tests Bullish Efficiency Narrative

Ryanair Holdings (ISE:RYA) sets the stage with Q3 2026 headline numbers Ryanair Holdings (ISE:RYA) has just reported its Q3 2026 results, with the latest available quarterly snapshot showing Q2 2026 revenue of €5.5b and basic EPS of €1.62. Trailing 12 month revenue stood at €15.1b and EPS at €2.20. Over recent quarters the company has seen revenue move from €3.6b in Q1 2025 to €5.1b in Q2 2025 and then to €5.5b in Q2 2026. EPS has shifted from €0.32 to €1.29 and then €1.62. This sets up the...
ISE:RYA
ISE:RYAAirlines

Should Legal Setbacks And Musk Feud Boost Require Action From Ryanair Holdings (ISE:RYA) Investors?

In recent weeks, Ryanair has faced a series of legal setbacks across Europe, including a fine from the Regional Court of Hamburg for failing to remove banned terms from its website and rulings against its non‑refundable fares, refund fees, and consent practices. At the same time, a high‑profile feud between CEO Michael O’Leary and Elon Musk has unexpectedly boosted Ryanair’s ticket sales, as the airline leverages the publicity through discounted seat promotions while reaffirming its low‑cost...
ISE:GVR
ISE:GVRConsumer Durables

Glenveagh Properties (ISE:GVR) Valuation After New Share Buyback And 2,000 Unit Output Guidance

Glenveagh Properties (ISE:GVR) has put two clear signals on the table: a new share buyback of up to €25 million and guidance to scale homebuilding output to about 2,000 units by 2027. See our latest analysis for Glenveagh Properties. Those capital return and growth plans come after a solid stretch of gains, with the share price at €2.01 and a 90 day share price return of 10.93%. The 1 year total shareholder return sits at 30.52% and the 5 year total shareholder return is 136.47%, suggesting...
ISE:IRES
ISE:IRESResidential REITs

European Small Caps With Insider Action Highlighting Undervalued Opportunities

As the pan-European STOXX Europe 600 Index reaches new heights, buoyed by an improving economic backdrop and marking its strongest yearly performance since 2021, investors are increasingly focusing on small-cap opportunities within this dynamic market landscape. In such a thriving environment, identifying stocks with strong fundamentals and insider activity can highlight potential undervalued opportunities in the European small-cap sector.
ISE:UPR
ISE:UPRHealthcare

Is Uniphar’s Rare-Disease Logistics Expansion with Zevra Reshaping the Investment Case for Uniphar (ISE:UPR)?

Zevra Therapeutics announced that it has entered into an exclusive expanded access distribution agreement with Ireland-based Uniphar, enabling Niemann-Pick Disease Type C patients in select territories outside Europe to obtain reimbursed named-patient supply of MIPLYFFA, the only approved therapy that targets the underlying pathology of this ultra-rare condition. The deal strengthens Uniphar’s position as a specialist partner for complex rare-disease logistics, highlighting its capabilities...